TOTomoya Oishi

Tomoya Oishi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tomoya Oishi has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Potential for enhanced oncolytic HSV-1 therapy via SHED as a vehicle against malignant gliomas

    by Satoru Kida, Tomoya Oishi, Tomohiro Yamasaki, Yoshinobu Kamio, Tomoya Sakamoto, Toru Kawakatsu, Shinichiro Koizumi, Masahiko Ito, Tetsuro Suzuki, Yoshihiro Otani, et al.

    Malignant gliomas are common primary brain tumors. Glioblastoma carries a poor prognosis, with median survival of less than 2 years. Given the urgent need for novel therapies, oncolytic virus (OV) therapy has developed rapidly. However, challenges remain with effective OV delivery to tumor sites and efficient infection of tumor cells. This study investigated the use of stem cells from human exfoliated deciduous teeth (SHED) as a potential vehicle for oncolytic herpes simplex virus-1 therapy (SHED-OV) to enhance treatment efficacy. SHED-OV showed a greater reduction in tumor cell viability in vitro than direct OV infection. Migration assays revealed that SHED-OV actively migrated toward glioma cell-conditioned medium, demonstrating their tumor-homing ability. In vivo experiments demonstrated significantly prolonged survival in both the glioma cell/SHED-OV co-implantation group and the OV-infected glioma cell group compared with controls. In a glioma stem cell model, both SHED-OV and OV alone significantly improved survival compared with controls, with SHED-OV achieving anti-tumor effects comparable to those of direct OV administration and complete tumor regression in a subset of mice. SHED-OV also exhibited tumor-homing ability. These results suggest that SHED could serve as an effective vehicle for OV delivery, potentially improving tumor infection and therapeutic efficacy.

  • Open Access

    Postoperative Writing Impairment in Glioma Patients Undergoing Awake Craniotomy

    by Tomoya Oishi, Shinichiro Koizumi, Dang Ngoc Phuong Dung, Tomohiro Yamasaki, Fumiya Ito, Miyu Iga, Chika Sato, Yoshiki Nakajima, Katsuya Yamauchi, Kazuhiko Kurozumi

  • Open Access

    Sigmoid sinus dural arteriovenous fistula presenting with pulsatile tinnitus in the postpartum period: A case report

    by Yoshinobu Kamio, Hiroaki Neki, Tomohiro Yamasaki, Tomoya Oishi, Yudai Yamashiro, Shinnosuke Fukami, Sayaka Ito, Kazuhiko Kurozumi

  • Mesenchymal stem cells as therapeutic vehicles for glioma

    by Tomoya Oishi, Shinichiro Koizumi, Kazuhiko Kurozumi

    Glioma is a disease with a poor prognosis despite the availability of multimodality treatments, and the development of novel therapies is urgently needed. Challenges in glioma treatment include the difficulty for drugs to cross the blood–brain barrier when administered systemically and poor drug diffusion when administered locally. Mesenchymal stem cells exhibit advantages for glioma therapy because of their ability to pass through the blood–brain barrier and migrate to tumor cells and their tolerance to the immune system. Therefore, mesenchymal stem cells have been explored as vehicles for various therapeutic agents for glioma treatment. Mesenchymal stem cells loaded with chemotherapeutic drugs show improved penetration and tumor accumulation. For gene therapy, mesenchymal stem cells can be used as vehicles for suicide genes, the so-called gene-directed enzyme prodrug therapy. Mesenchymal stem cell-based oncolytic viral therapies have been attempted in recent years to enhance the efficacy of infection against the tumor, viral replication, and distribution of viral particles. Many uncertainties remain regarding the function and behavior of mesenchymal stem cells in gliomas. However, strategies to increase mesenchymal stem cell migration to gliomas may improve the delivery of therapeutic agents and enhance their anti-tumor effects, representing promising potential for patient treatment.